Accentia shares soar on cancer trial results

Shares of Accentia Biopharmaceuticals soared 54 percent Thursday after the drug developer announced positive results from a small clinical trial of its BiovaxId cancer therapy for relapsed Follicular Non-Hodgkins Lymphoma. In the trial, 20 patients, or 80 percent, who took BiovaxId following chemotherapy saw their cancer go into remission for 20 to 51 months. The drug relied on the patient's cells to create a therapy that is designed to get the immune system to recognize the cancer and attack it.

- here's the AP report on Accentia

Related Article
In May the FDA granted fast track status to Accentia's drug. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.